Icotinib (Conmana) was associated with a 3.3-month increase in median progression-free survival (PFS) compared with chemotherapy in patients with stage IIIB/IV non–small cell lung cancer (NSCLC) in the phase III Chinese CONVINCE trial.
<.001). Those patients were also more than 8 times more likely to require drug discontinuation due to AEs (17.5% vs 2%).
Shi YK, Wang L, Han BH, et al. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study [published online August 23, 2017]. Ann Oncol. doi: 10.1093/annonc/mdx359.
... to read the full story